Pluristem Therapeutics Inc. (PSTI)

0.57
0.00 0.69
NASDAQ : Health Technology
Prev Close 0.57
Open 0.57
Day Low/High 0.56 / 0.57
52 Wk Low/High 0.50 / 1.38
Volume 51.40K
Avg Volume 627.00K
Exchange NASDAQ
Shares Outstanding 149.74M
Market Cap 84.26M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
Pluristem To Deliver Key Commercialization And Scientific Presentations At International Society For Cellular Therapy Conference 2014

Pluristem To Deliver Key Commercialization And Scientific Presentations At International Society For Cellular Therapy Conference 2014

Pluristem's Dr. Ohad Karnieli Confirmed as Chair of ISCT's Influential Process and Product Committee for a 2-Year Post

Preclinical Results For Pluristem's PLX-PAD Cells In Tendon Injury Presented At American Academy Of Orthopedic Surgeons' Annual Meeting

Preclinical Results For Pluristem's PLX-PAD Cells In Tendon Injury Presented At American Academy Of Orthopedic Surgeons' Annual Meeting

Independent Study Shows Use of PLX-PAD Human Placental-Derived Adherent Stromal Cells Improves Tendon Healing in a Preclinical Model of Tendon Injury

Pluristem CEO Zami Aberman To Present On Cell & Gene Therapy Panel Discussion At BIO-Europe Spring 2014

Pluristem CEO Zami Aberman To Present On Cell & Gene Therapy Panel Discussion At BIO-Europe Spring 2014

Aberman to Discuss Collaborative Models and Partnerships That Enable Successful Commercialization of Gene and Cell Therapies

US FDA Approves Pluristem's Commercial Scale Cell Manufacturing Process

US FDA Approves Pluristem's Commercial Scale Cell Manufacturing Process

Pluristem Fortifies Leadership Position in Cell Therapy Following Multiple Regulatory Approvals of Its New PLX Cell Mass Production Facility

Pluristem Submits FDA Orphan Drug Application For Preeclampsia

Pluristem Submits FDA Orphan Drug Application For Preeclampsia

Orphan Drug Designation May Provide Benefits Including 7 Year Market Exclusivity, Tax Credits, and FDA's Guidance on Clinical Studies

Pluristem Receives Key 3D Cell Expansion Patent In Australia

Pluristem Receives Key 3D Cell Expansion Patent In Australia

Covers Commercial Rights for 3D Manufacturing Methods and Composition of Matter for Placental or Fat Cells

Pluristem CEO Zami Aberman To Speak On Panel At 9th Annual Stem Cell Summit On February 18, 2014

Pluristem CEO Zami Aberman To Speak On Panel At 9th Annual Stem Cell Summit On February 18, 2014

Panel: Disrupting the Pharma Model With Allogeneic Stem Cell Therapies

Medical Key Opinion Leaders In Preeclampsia Join Pluristem's Steering Committee

Medical Key Opinion Leaders In Preeclampsia Join Pluristem's Steering Committee

PLX-PAD Cells Offer Promising Potential Treatment for Preeclampsia; Currently no Treatment Exists Other Than Early Delivery

U.S. National Institutes Of Health To Commence New Study Of Pluristem's PLX Cells For Acute Radiation Syndrome Treatment

U.S. National Institutes Of Health To Commence New Study Of Pluristem's PLX Cells For Acute Radiation Syndrome Treatment

NIAID's Next Study of PLX-RAD Cells to be Initiated in February

Pluristem CEO Seeing the Future in 3D Cells

Pluristem CEO Seeing the Future in 3D Cells

Pluristem's successful stem cell trial last week on muscle injuries is an important first step for the company, says the company's CEO Zami Aberman.

Pluristem CEO Zami Aberman To Present At Phacilitate Cell & Gene Therapy Forum 2014

Pluristem CEO Zami Aberman To Present At Phacilitate Cell & Gene Therapy Forum 2014

Aberman to Share Pluristem's Expertise in Cell Therapies at Four Sessions During the Three Day Conference

First Week Of PSTI September 20th Options Trading

First Week Of PSTI September 20th Options Trading

Investors in Pluristem Therapeutics Inc saw new options begin trading this week, for the September 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Pluristem's Cell Manufacturing Facility Marks Major Milestone With German Regulatory Approval Of New Scaled-Up 3D Manufacturing Process

Pluristem's Cell Manufacturing Facility Marks Major Milestone With German Regulatory Approval Of New Scaled-Up 3D Manufacturing Process

First of Many Expected Regulatory Approvals for the New Facility Strengthens Pluristem's Leadership Position in Commercial-Scale Cell Manufacturing Technologies

Pluristem's Phase I/II Muscle Injury Trial Successfully Meets Primary Safety & Efficacy Endpoints

Pluristem's Phase I/II Muscle Injury Trial Successfully Meets Primary Safety & Efficacy Endpoints

PLX-PAD Cells Show Statistically Significant Improvement Over Placebo in the Change of the Maximal Contraction Force of the Gluteal Muscle

Pluristem Receives Key Placental Cell Therapy Patent In Australia

Pluristem Receives Key Placental Cell Therapy Patent In Australia

Broad Patent Addresses Several Pluristem Indications in Clinical Development

Results Of Pluristem's Phase I/II Muscle Injury Trial To Be Announced On January 21, 2014

Results Of Pluristem's Phase I/II Muscle Injury Trial To Be Announced On January 21, 2014

Principal Investigator of the Study Will Join Pluristem Management to Announce Results at the Tel Aviv Stock Exchange

Pluristem Receives Regulatory Approval To Extend Its Phase II Study Of PLX-PAD Cells In The Treatment Of Intermittent Claudication To South Korea

Pluristem Receives Regulatory Approval To Extend Its Phase II Study Of PLX-PAD Cells In The Treatment Of Intermittent Claudication To South Korea

CHA Bio Will Conduct and Fund the Trial; PLX-PAD Cells Are the First Placental-Derived Allogeneic Cells Approved for Importation Into South Korea

Safety Of Pluristem's PLX Cells Demonstrated In Pre-Clinical Pregnancy Model

Safety Of Pluristem's PLX Cells Demonstrated In Pre-Clinical Pregnancy Model

Important Milestone Advances Pluristem's Clinical Development Program for the Treatment of Preeclampsia Using PLX-PAD Cells

Pluristem Receives Israeli Ministry Of Health Approval To Expand Its Phase II Clinical Trial In Intermittent Claudication To Israel

Pluristem Receives Israeli Ministry Of Health Approval To Expand Its Phase II Clinical Trial In Intermittent Claudication To Israel

International Study Extends FDA Phase II Trial That Began in U.S.

Pluristem Granted Key U.S. Patent For The Treatment Of Peripheral Artery Disease

Pluristem Granted Key U.S. Patent For The Treatment Of Peripheral Artery Disease

Exclusive Rights to Treat PAD With Placental Cells in the U.S.

TheStreet Quant Rating: D- (Sell)